5:46 PM
 | 
Oct 28, 2013
 |  BC Extra  |  Clinical News

Synta slides on updated ganetespib data

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) fell $1.30 (20%) to $5.10 on Monday after reporting updated data from the Phase IIb/III GALAXY-1 trial evaluating ganetespib (formerly STA-9090) as second-line treatment for advanced, metastatic non-small cell lung cancer (NSCLC). The data came from 178 stage IIIB/IV NSCLC adenocarcinoma patients who were enrolled more than six months after diagnosis of disease -- the population Synta chose...

Read the full 296 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >